Concomitant Use of the Oral Pentavalent Human-Bovine Reassortant Rotavirus Vaccine and Oral Poliovirus Vaccine

Abstract

PRV did not interfere with immune responses to OPV. Although coadministration with OPV reduced serum antirotavirus IgA geometric mean titer, seroresponse rates were high and consistent with those observed in previous studies showing high vaccine efficacy. These results support including PRV in vaccination schedules involving OPV.

Risk of Intussusception After Rotavirus Vaccination

“…In the case of the study by Patel et al (18), only data from Mexico were included; the results from Brazil were ignored, because in Brazil the oral polio vaccine (OPV) was given in parallel with the first dose of RV vaccine. Administration of these two live vaccines in parallel appears to reduce the immunogenicity of the RV vaccine and therefore also to mask the possible intussusception risk (35).…”

Results from a Randomized Clinical Trial of Coadministration of RotaTeq, a Pentavalent Rotavirus Vaccine, and NeisVac-C, a Meningococcal Serogroup C Conjugate Vaccine

“…Concomitant administration of vaccines has several potential benefits, including (i) reduction of costs associated with extra health visits and (ii) facilitating the addition of new vaccines to immunization programs. RotaTeq has been demonstrated to be immunogenic and well tolerated when it is given alone or concomitantly with other routine childhood vaccines (4,5,17). The SmPC of RotaTeq has been updated to include concomitant administration of RotaTeq and MenCC.…”

“…It is a live attenuated human-bovine reassortant rotavirus vaccine consisting of the genes encoding the G1, G2, G3, G4, and P1A [8] outer capsid proteins of human rotaviruses in monoreassortants containing a bovine rotavirus genetic background. RotaTeq has been demonstrated to be efficacious, immunogenic, and well tolerated when it is given alone or concomitantly with routine childhood vaccines (4,5,17,21,22,23,24). On the basis of the current summary of product characteristics (SmPC) for RotaTeq in Europe, the first dose should be given at between 6 weeks and 12 weeks of age and all three doses should be given before 26 weeks of age (13).…”

“…The concomitant use of RotaTeq with licensed pediatric vaccines, including diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP), inactivated poliovirus vaccine (IPV), Haemophilus influenzae type b conjugate vaccine (Hib), hepatitis B vaccine, hexavalent vaccine (combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, H. influenzae type b, and hepatitis B), pneumococcal conjugate vaccine, and oral poliomyelitis vaccine, has been evaluated in phase III clinical trials (4,5,17). Meningococcal serogroup C conjugate vaccine (MenCC) was not used routinely in the countries in which the initial studies with RotaTeq were undertaken; consequently, the concomitant administration of RotaTeq with MenCC has not been investigated (2,21,23).…”

Safety and immunogenicity of pentavalent rotavirus vaccine in a randomized, double-blind, placebo-controlled study in healthy elderly subjects

“…15,[26][27][28] Study outcomes A primary objective of the study was to evaluate the safety of RV5 in healthy adult subjects 65-80 y of age, who were cognitively competent and independently living outside a long-term care facility, with respect to all NSAEs up to 42 d after any dose, and SAEs up to 180 d after the third dose of RV5 or placebo. Analysis of immunogenicity of RV5 after 1, 2, or 3 doses of RV5 or placebo was a co-primary objective of the study.…”